-
Zephyrm Bioscience Limited Files for IPO on Hong Kong Stock Exchange
•
China-based Zephyrm Bioscience Limited, a biopharmaceutical company specializing in the development of novel pluripotent stem cell (PSC) derived cell therapies, has filed for an initial public offering (IPO) on the Hong Kong Stock Exchange. Details of the offering have not been disclosed at this stage. Established in 2017, Zephyrm Bio…
-
Zephyrm Bioscience Aims for HKEX Main Board with Innovative Cell Therapy Products
•
Zephyrm Bioscience Limited (hereinafter referred to as “Zephyrm Bio”) officially submitted its prospectus to the Hong Kong Stock Exchange (HKEX) on September 30, 2024, with the intention to list on the Main Board, with CICC acting as the sole sponsor. Established in 2017, Zephyrm Bio, a clinical-stage biopharmaceutical company, is…
-
Zephyrm Bioscience Secures Over RMB 200 Million in Series B Financing for Stem-Cell Drug Development
•
Zephyrm Bioscience, a prominent stem cell drug developer headquartered in Suzhou, has reportedly secured more than RMB 200 million (USD 29.1 million) in a Series B financing round. This significant investment, led by CCB Trust, will fuel the company’s efforts in advancing stem-cell drugs for a variety of diseases and…
